Bortezomib and osteoclasts and osteoblasts

Michal T. Krauze, G. David Roodman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Bortezomib is the first-in-class proteasome antagonist approved for treatment of myeloma. It is active in newly diagnosed, relapsed, and refractory patients and is now being used as a platform for combinations with other new agents for myeloma. In addition to its anti-myeloma effect, bortezomib also targets the bone microenvironment and can inhibit osteoclast formation and stimulate osteoblast activity in patients with myeloma. Potentially, combination of bortezomib with other agents that stimulate bone formation or block bone resorption will further enhance the anti-myeloma effects of bortezomib and overcome the contribution of the tumor microenvironment to myeloma growth. In this chapter, we discuss the potential mechanisms responsible for bortezomib's effects on osteoclast and osteoblast activity in myeloma.

Original languageEnglish (US)
Title of host publicationMilestones in Drug Therapy
Pages43-52
Number of pages10
Volume37
StatePublished - 2011
Externally publishedYes

Publication series

NameMilestones in Drug Therapy
Volume37

Fingerprint

Osteoclasts
Osteoblasts
Tumor Microenvironment
Proteasome Endopeptidase Complex
Bone Resorption
Osteogenesis
Bortezomib
Bone and Bones
Growth

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Drug Discovery

Cite this

Krauze, M. T., & Roodman, G. D. (2011). Bortezomib and osteoclasts and osteoblasts. In Milestones in Drug Therapy (Vol. 37, pp. 43-52). (Milestones in Drug Therapy; Vol. 37).

Bortezomib and osteoclasts and osteoblasts. / Krauze, Michal T.; Roodman, G. David.

Milestones in Drug Therapy. Vol. 37 2011. p. 43-52 (Milestones in Drug Therapy; Vol. 37).

Research output: Chapter in Book/Report/Conference proceedingChapter

Krauze, MT & Roodman, GD 2011, Bortezomib and osteoclasts and osteoblasts. in Milestones in Drug Therapy. vol. 37, Milestones in Drug Therapy, vol. 37, pp. 43-52.
Krauze MT, Roodman GD. Bortezomib and osteoclasts and osteoblasts. In Milestones in Drug Therapy. Vol. 37. 2011. p. 43-52. (Milestones in Drug Therapy).
Krauze, Michal T. ; Roodman, G. David. / Bortezomib and osteoclasts and osteoblasts. Milestones in Drug Therapy. Vol. 37 2011. pp. 43-52 (Milestones in Drug Therapy).
@inbook{210b287e633d420184909945a3ab5418,
title = "Bortezomib and osteoclasts and osteoblasts",
abstract = "Bortezomib is the first-in-class proteasome antagonist approved for treatment of myeloma. It is active in newly diagnosed, relapsed, and refractory patients and is now being used as a platform for combinations with other new agents for myeloma. In addition to its anti-myeloma effect, bortezomib also targets the bone microenvironment and can inhibit osteoclast formation and stimulate osteoblast activity in patients with myeloma. Potentially, combination of bortezomib with other agents that stimulate bone formation or block bone resorption will further enhance the anti-myeloma effects of bortezomib and overcome the contribution of the tumor microenvironment to myeloma growth. In this chapter, we discuss the potential mechanisms responsible for bortezomib's effects on osteoclast and osteoblast activity in myeloma.",
author = "Krauze, {Michal T.} and Roodman, {G. David}",
year = "2011",
language = "English (US)",
isbn = "9783764389475",
volume = "37",
series = "Milestones in Drug Therapy",
pages = "43--52",
booktitle = "Milestones in Drug Therapy",

}

TY - CHAP

T1 - Bortezomib and osteoclasts and osteoblasts

AU - Krauze, Michal T.

AU - Roodman, G. David

PY - 2011

Y1 - 2011

N2 - Bortezomib is the first-in-class proteasome antagonist approved for treatment of myeloma. It is active in newly diagnosed, relapsed, and refractory patients and is now being used as a platform for combinations with other new agents for myeloma. In addition to its anti-myeloma effect, bortezomib also targets the bone microenvironment and can inhibit osteoclast formation and stimulate osteoblast activity in patients with myeloma. Potentially, combination of bortezomib with other agents that stimulate bone formation or block bone resorption will further enhance the anti-myeloma effects of bortezomib and overcome the contribution of the tumor microenvironment to myeloma growth. In this chapter, we discuss the potential mechanisms responsible for bortezomib's effects on osteoclast and osteoblast activity in myeloma.

AB - Bortezomib is the first-in-class proteasome antagonist approved for treatment of myeloma. It is active in newly diagnosed, relapsed, and refractory patients and is now being used as a platform for combinations with other new agents for myeloma. In addition to its anti-myeloma effect, bortezomib also targets the bone microenvironment and can inhibit osteoclast formation and stimulate osteoblast activity in patients with myeloma. Potentially, combination of bortezomib with other agents that stimulate bone formation or block bone resorption will further enhance the anti-myeloma effects of bortezomib and overcome the contribution of the tumor microenvironment to myeloma growth. In this chapter, we discuss the potential mechanisms responsible for bortezomib's effects on osteoclast and osteoblast activity in myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84867039321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867039321&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84867039321

SN - 9783764389475

VL - 37

T3 - Milestones in Drug Therapy

SP - 43

EP - 52

BT - Milestones in Drug Therapy

ER -